Article number: K 7828



Pack size

96 Tests

Standard concentrations included in the kit

0.1-2.0 µmol/l

Possible sample matrix and volumes

EDTA plasma 50 µl
Serum 50 µl
Citrate plasma 50 µl

Incubation periods

  1. 45 minutes
  2. 45 minutes
  3. 15-20 hours
  4. 1 hour
  5. 6-10 minutes


Regulatory Status

CE marked

For further information please contact

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of NO synthesis, an enzyme that catalyses the production of nitric oxide from the amino acid arginine. Nitric oxide (NO) is one of the major endothelium-derived vasoactive mediators and is involved in the modulation of the blood flow and the blood pressure. Even small changes of the ADMA concentration alter vascular NO production, vascular tone, and systemic vascular resistence. Because of these properties NO has also been described as an "endogenous anti-atherosclerotic molecule".
Elevated ADMA concentrations are found in patients with diabetes mellitus, hyperchoesterolemia, hypertension, pulmonary hypertension, peripheral arterial disease, chronic renal failure, preeclampsia or erectile dysfunction.
ADMA was found to predict cardiovascular risk independently of other variables. It has thus been concluded that ADMA is a novel cardiovascular risk factor.